People: Nektar Therapeutics (NKTR.O)
9.81USD
18 Jun 2013
$0.48 (+5.14%)
$9.33
$9.38
$9.81
$9.21
519,421
885,013
$11.34
$5.65
Robin, Howard
Brief Biography
Mr. Howard W. Robin is President, Chief Executive Officer, Director of Nektar Therapeutics. He has served as President and Chief Executive Officer since January 2007 and has served as a member of board of directors since February 2007. Mr. Robin served as Chief Executive Officer, President and a director of Sirna Therapeutics, Inc., a biotechnology company, from July 2001 to November 2006 and from January 2001 to June 2001, served as their Chief Operating Officer, President and as director. From 1991 to 2001, Mr. Robin was Corporate Vice President and General Manager at Berlex Laboratories, Inc., a pharmaceutical products company that is a subsidiary of Schering, AG, and from 1987 to 1991 he served as Vice President of Finance and Business Development and Chief Financial Officer. From 1984 to 1987, Mr. Robin was Director of Business Planning and Development at Berlex. He was a Senior Associate with Arthur Andersen & Co. prior to joining Berlex. Mr. Robin serves as a director of the Biotechnology Industry Organization, the world’s biotechnology industry trade organization, and also serves as a director of BayBio, a non-profit trade association serving the Northern California life sciences community. He received his B.S. in Accounting and Finance from Fairleigh Dickinson University in 1974.
Basic Compensation
| Total Annual Compensation, USD | Long-Term Incentive Plans, USD | All Other, USD | Fiscal Year Total, USD |
|---|---|---|---|
| 1,435,130 | -- | 1,747,500 | 3,182,630 |
Options Compensation
| Quantity | Market Value | |
|---|---|---|
| Excercisable | -- | -- |
| Unexercisable | -- | -- |
| Excercised | -- | -- |
| Name | Fiscal Year Total |
|---|---|
Robert Chess |
1,468,750 |
Howard Robin |
3,182,630 |
John Nicholson |
1,137,880 |
Jillian Thomsen |
-- |
Stephen Doberstein |
1,025,630 |
Gil Labrucherie |
1,310,530 |

